Skip to main content
Erschienen in: Journal of General Internal Medicine 2/2017

19.10.2016 | Review Paper

Pre-Exposure Prophylaxis: A Narrative Review of Provider Behavior and Interventions to Increase PrEP Implementation in Primary Care

verfasst von: Andrew Silapaswan, BS, Douglas Krakower, MD, Kenneth H. Mayer, MD

Erschienen in: Journal of General Internal Medicine | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Since FDA approval of HIV pre-exposure prophylaxis (PrEP) for HIV prevention, attention has been focused on PrEP implementation. The CDC estimates that 1.2 million U.S. adults might benefit from PrEP, but only a minority are using PrEP, so there is a significant unmet need to increase access for those at risk for HIV. Given the large numbers of individuals who have indications for PrEP, there are not enough practicing specialists to meet the growing need for providers trained in providing PrEP. Moreover, since PrEP is a preventive intervention for otherwise healthy individuals, primary care providers (PCPs) should be primary prescribers of PrEP. There are important clinical considerations that providers should take into account when planning to prescribe PrEP, which are highlighted in the clinical case discussed. A growing body of research also suggests that some providers may be cautious about prescribing PrEP because of concerns regarding its “real-world” effectiveness, anticipated unintended consequences associated with its use, and ambiguity as to who should prescribe it. This review summarizes findings from studies that have assessed prescriber behavior regarding provision of PrEP, and offers recommendations on how to optimize PrEP implementation in primary care settings. Development and dissemination of educational interventions for PCPs and potential PrEP users are needed, including improved methods to assist clinicians in identifying appropriate PrEP candidates, and programs to promote medication adherence and access to social and behavioral health services. PCPs are well-positioned to prescribe PrEP and coordinate health-related services to improve the sexual health of their patients, but tailored educational programs are needed.
Literatur
4.
Zurück zum Zitat Tellalian D, Maznavi K, Bredeek UF, Hardy WD. Pre-exposure prophylaxis (PrEP) for HIV infection: results of a survey of HIV healthcare providers evaluating their knowledge, attitudes, and prescribing practices. AIDS Patient Care STDs. 2013;27(10):1–7.CrossRef Tellalian D, Maznavi K, Bredeek UF, Hardy WD. Pre-exposure prophylaxis (PrEP) for HIV infection: results of a survey of HIV healthcare providers evaluating their knowledge, attitudes, and prescribing practices. AIDS Patient Care STDs. 2013;27(10):1–7.CrossRef
5.
Zurück zum Zitat Karris MY, Beekmann SE, Mehta SR, Anderson CM, Polgreen PM. Are we prepped for preexposure prophylaxis (PrEP)? Provider opinions on the real-world use of PrEP in the United States and Canada. Clin Infect Dis. 2014;58(5):704–12.CrossRefPubMed Karris MY, Beekmann SE, Mehta SR, Anderson CM, Polgreen PM. Are we prepped for preexposure prophylaxis (PrEP)? Provider opinions on the real-world use of PrEP in the United States and Canada. Clin Infect Dis. 2014;58(5):704–12.CrossRefPubMed
6.
Zurück zum Zitat Krakower DS, Beekmann SE, Polgreen PM, Mayer KH. Frontline practices with HIV prevention: A survey of U.S. infectious disease physicians. Conference on retroviruses and opportunistic infections [abstract 1083]. Seattle, Washington: 2015; 23–26 February. Krakower DS, Beekmann SE, Polgreen PM, Mayer KH. Frontline practices with HIV prevention: A survey of U.S. infectious disease physicians. Conference on retroviruses and opportunistic infections [abstract 1083]. Seattle, Washington: 2015; 23–26 February.
7.
Zurück zum Zitat Arnold EA, Hazelton P, Lane T, et al. A qualitative study of provider thoughts on implementing pre-exposure prophylaxis (PrEP) in clinical settings to prevent HIV infection. PLoS ONE. 2012;7(7):e40603.CrossRefPubMedPubMedCentral Arnold EA, Hazelton P, Lane T, et al. A qualitative study of provider thoughts on implementing pre-exposure prophylaxis (PrEP) in clinical settings to prevent HIV infection. PLoS ONE. 2012;7(7):e40603.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat White JM, Mimiaga MJ, Krakower DS, Mayer KH. Evolution of Massachusetts physician attitudes, knowledge, and experience regarding the use of antiretrovirals for HIV prevention. AIDS Patient Care STDs. 2012;26(7):395–405.PubMedPubMedCentral White JM, Mimiaga MJ, Krakower DS, Mayer KH. Evolution of Massachusetts physician attitudes, knowledge, and experience regarding the use of antiretrovirals for HIV prevention. AIDS Patient Care STDs. 2012;26(7):395–405.PubMedPubMedCentral
9.
Zurück zum Zitat Krakower DS, Ware N, Mitty JA, Maloney K, Mayer KH. HIV providers’ perceived barriers and facilitators to implementing pre-exposure prophylaxis in care settings: a qualitative sutdy. AIDS Behav. 2014;18(9):1712–21.CrossRefPubMedPubMedCentral Krakower DS, Ware N, Mitty JA, Maloney K, Mayer KH. HIV providers’ perceived barriers and facilitators to implementing pre-exposure prophylaxis in care settings: a qualitative sutdy. AIDS Behav. 2014;18(9):1712–21.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Krakower DS, Oldenburg CE, Mitty JA, et al. Knowledge, beliefs and practices regarding antiretroviral medications for HIV prevention: results from a survey of healthcare providers in New England. PLoS ONE. 2015;10(7):1–15.CrossRef Krakower DS, Oldenburg CE, Mitty JA, et al. Knowledge, beliefs and practices regarding antiretroviral medications for HIV prevention: results from a survey of healthcare providers in New England. PLoS ONE. 2015;10(7):1–15.CrossRef
11.
Zurück zum Zitat Hoffman S, Guidry JA, Collier KL, et al. A clinical home for preexposure prophylaxis: diverse health care providers’ perspectives on the “purview paradox”. J Int Assoc Provid AIDS Care. 2016;15(1):59–65.CrossRefPubMed Hoffman S, Guidry JA, Collier KL, et al. A clinical home for preexposure prophylaxis: diverse health care providers’ perspectives on the “purview paradox”. J Int Assoc Provid AIDS Care. 2016;15(1):59–65.CrossRefPubMed
12.
13.
Zurück zum Zitat Mayer KH, Hosek S, Cohen S, et al. Antiretroviral pre-exposure prophylaxis implementation in the United States: a work in progress. J Int AIDS Soc. 2015;18(4 Suppl 3):1–7. Mayer KH, Hosek S, Cohen S, et al. Antiretroviral pre-exposure prophylaxis implementation in the United States: a work in progress. J Int AIDS Soc. 2015;18(4 Suppl 3):1–7.
14.
Zurück zum Zitat Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.CrossRefPubMedPubMedCentral Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Molina JM, Capitant C, Spire B, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015;373(23):2237–46.CrossRefPubMed Molina JM, Capitant C, Spire B, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015;373(23):2237–46.CrossRefPubMed
16.
Zurück zum Zitat Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423–34.CrossRefPubMed Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423–34.CrossRefPubMed
17.
Zurück zum Zitat Grohskopf LA, Chillag KL, Gvetadze R, et al. Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States. J Acquir Immune Defic Syndr. 2013;64(1):79–86.CrossRefPubMed Grohskopf LA, Chillag KL, Gvetadze R, et al. Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States. J Acquir Immune Defic Syndr. 2013;64(1):79–86.CrossRefPubMed
18.
Zurück zum Zitat Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410.CrossRefPubMedPubMedCentral Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083–90.CrossRefPubMed Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083–90.CrossRefPubMed
20.
Zurück zum Zitat Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372:509–18.CrossRefPubMedPubMedCentral Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372:509–18.CrossRefPubMedPubMedCentral
21.
23.
Zurück zum Zitat Anderson PL, Glidden DV, Liu A, et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 2012;4(151):151ra125.CrossRefPubMedPubMedCentral Anderson PL, Glidden DV, Liu A, et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 2012;4(151):151ra125.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat McCormack S, Dunn DT, Desai M, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomized trial. Lancet. 2016;387(10013):53–60.CrossRefPubMedPubMedCentral McCormack S, Dunn DT, Desai M, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomized trial. Lancet. 2016;387(10013):53–60.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Volk JE, Marcus JL, Phengrasamy T, et al. No new HIV infections with increasing use of HIV preexposure prophylaxis in a clinical practice setting. Clin Infect Dis. 2015;61(10):1601–3.CrossRefPubMedPubMedCentral Volk JE, Marcus JL, Phengrasamy T, et al. No new HIV infections with increasing use of HIV preexposure prophylaxis in a clinical practice setting. Clin Infect Dis. 2015;61(10):1601–3.CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Marcus JL, Hurley LB, Hare CB, et al. HIV preexposure prophylaxis: Adherence and discontinuation in clinical practice. Conference on retroviruses and opportunistic infections [abstract 894]. Boston, Massachusetts: 2016; 22–25 February. Marcus JL, Hurley LB, Hare CB, et al. HIV preexposure prophylaxis: Adherence and discontinuation in clinical practice. Conference on retroviruses and opportunistic infections [abstract 894]. Boston, Massachusetts: 2016; 22–25 February.
27.
Zurück zum Zitat Grant RM, Anderson PL, McMahan V, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14(9):820–9.CrossRefPubMed Grant RM, Anderson PL, McMahan V, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14(9):820–9.CrossRefPubMed
28.
Zurück zum Zitat Hosek S, Rudy B, Landovitz R, et al. An HIV pre-exposure prophylaxis (PrEP) demonstration project and safety study for young men who have sex with men in the United States (ATN 110). IAS Conference on HIV Pathogenesis, Treatment & Prevention [abstract TUAC0204LB]. Vancouver, Canada: 2015; 19–22 July. Hosek S, Rudy B, Landovitz R, et al. An HIV pre-exposure prophylaxis (PrEP) demonstration project and safety study for young men who have sex with men in the United States (ATN 110). IAS Conference on HIV Pathogenesis, Treatment & Prevention [abstract TUAC0204LB]. Vancouver, Canada: 2015; 19–22 July.
29.
Zurück zum Zitat Patterson KB, Prince HA, Kraft E, et al. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med. 2011;3(112):112re4.CrossRefPubMedPubMedCentral Patterson KB, Prince HA, Kraft E, et al. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med. 2011;3(112):112re4.CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Amico KR, Mansoor LE, Corneli A, Torjesen K, Van Der Straten A. Adherence support approaches in biomedical HIV prevention trials: experiences, insights and future directions from four multisite prevention trials. AIDS Behav. 2013;17(6):2143–55.CrossRefPubMedPubMedCentral Amico KR, Mansoor LE, Corneli A, Torjesen K, Van Der Straten A. Adherence support approaches in biomedical HIV prevention trials: experiences, insights and future directions from four multisite prevention trials. AIDS Behav. 2013;17(6):2143–55.CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Koenig HC, Mounzer K, Daughtridge GW, et al. Urine assay for tenofovir to monitor adherence to tenofovir-emtricitabine as PrEP. Conference on retroviruses and opportunistic infections [abstract 975]. Seattle, Washington: 2015; 23–26 February. Koenig HC, Mounzer K, Daughtridge GW, et al. Urine assay for tenofovir to monitor adherence to tenofovir-emtricitabine as PrEP. Conference on retroviruses and opportunistic infections [abstract 975]. Seattle, Washington: 2015; 23–26 February.
33.
Zurück zum Zitat Horberg M, Raymond B. Financial policy issues for HIV pre-exposure prophylaxis. Am J Prev Med. 2013;44(1):S125–8.CrossRefPubMed Horberg M, Raymond B. Financial policy issues for HIV pre-exposure prophylaxis. Am J Prev Med. 2013;44(1):S125–8.CrossRefPubMed
35.
Zurück zum Zitat Grant RM, Liegler T. Weighing the risk of drug resistance with the benefits of HIV preexposure prophylaxis. J Infect Dis. 2015;211(8):1202–4.PubMedPubMedCentral Grant RM, Liegler T. Weighing the risk of drug resistance with the benefits of HIV preexposure prophylaxis. J Infect Dis. 2015;211(8):1202–4.PubMedPubMedCentral
36.
Zurück zum Zitat Weis JF, Baeten JM, Mccoy CO, et al. Preexposure prophylaxis-selected drug resistance decays rapidly after drug cessation. AIDS. 2016;30(1):31–5.CrossRefPubMedPubMedCentral Weis JF, Baeten JM, Mccoy CO, et al. Preexposure prophylaxis-selected drug resistance decays rapidly after drug cessation. AIDS. 2016;30(1):31–5.CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat Dimitrov D, Boily MC, Brown ER, Hallett TB. Analytic review of modeling studies of ARV based PrEP interventions reveals strong influence of drug-resistance assumptions on the population-level effectiveness. PLoS ONE. 2013;8(11):e80927.CrossRefPubMedPubMedCentral Dimitrov D, Boily MC, Brown ER, Hallett TB. Analytic review of modeling studies of ARV based PrEP interventions reveals strong influence of drug-resistance assumptions on the population-level effectiveness. PLoS ONE. 2013;8(11):e80927.CrossRefPubMedPubMedCentral
38.
Zurück zum Zitat van de Vijver DA, Nichols BE, Abbas UL, et al. Pre-exposure prophylaxis (PrEP) will have a limited impact on the prevalence of HIV-1 drug resistance in sub-Saharan Africa: a comparison of mathematical models. AIDS. 2013;27(18):2943–51.CrossRefPubMed van de Vijver DA, Nichols BE, Abbas UL, et al. Pre-exposure prophylaxis (PrEP) will have a limited impact on the prevalence of HIV-1 drug resistance in sub-Saharan Africa: a comparison of mathematical models. AIDS. 2013;27(18):2943–51.CrossRefPubMed
39.
Zurück zum Zitat Desai M, Gafos M, Dolling D, McCormack S, Nardone A. Healthcare providers’ knowledge of, attitudes to and practice of pre-exposure prophylaxis for HIV infection. HIV Med. 2016;17(2):133–42.CrossRefPubMed Desai M, Gafos M, Dolling D, McCormack S, Nardone A. Healthcare providers’ knowledge of, attitudes to and practice of pre-exposure prophylaxis for HIV infection. HIV Med. 2016;17(2):133–42.CrossRefPubMed
40.
Zurück zum Zitat Knox DC, Tan DH, Harrigan PR, Anderson PL. HIV-1 infection with multiclass resistance despite preexposure prophylaxis (PrEP). Conference on retroviruses and opportunistic infections [abstract 169aLB]. Boston, Massachusetts: 2016; 22–25 February. Knox DC, Tan DH, Harrigan PR, Anderson PL. HIV-1 infection with multiclass resistance despite preexposure prophylaxis (PrEP). Conference on retroviruses and opportunistic infections [abstract 169aLB]. Boston, Massachusetts: 2016; 22–25 February.
41.
Zurück zum Zitat Glidden DV, Rivet AK, Liu AY, et al. Symptoms, side effects and adherence in the iPrEx open-label extension. Clin Infect Dis. 2016;62(9):1172–7.CrossRefPubMed Glidden DV, Rivet AK, Liu AY, et al. Symptoms, side effects and adherence in the iPrEx open-label extension. Clin Infect Dis. 2016;62(9):1172–7.CrossRefPubMed
42.
Zurück zum Zitat Gandhi M, Glidden DV, Liu AY, et al. Higher cumulative TFV/FTC levels in PrEP associated with decline in renal function. Conference on retroviruses and opportunistic infections [abstract 866]. Boston, Massachusetts: 2016; 22–25 February. Gandhi M, Glidden DV, Liu AY, et al. Higher cumulative TFV/FTC levels in PrEP associated with decline in renal function. Conference on retroviruses and opportunistic infections [abstract 866]. Boston, Massachusetts: 2016; 22–25 February.
43.
Zurück zum Zitat Mugwanya KK, Wyatt C, Celum C, et al. Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial. JAMA Intern Med. 2015;175(2):246–54.CrossRefPubMedPubMedCentral Mugwanya KK, Wyatt C, Celum C, et al. Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial. JAMA Intern Med. 2015;175(2):246–54.CrossRefPubMedPubMedCentral
44.
Zurück zum Zitat Solomon MM, Lama JR, Glidden DV, et al. Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis. AIDS. 2014;28(6):851–9.CrossRefPubMedPubMedCentral Solomon MM, Lama JR, Glidden DV, et al. Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis. AIDS. 2014;28(6):851–9.CrossRefPubMedPubMedCentral
45.
Zurück zum Zitat Mulligan K, Glidden DV, Anderson PL, et al. Effects of emtricitabine/tenofovir on bone mineral density in HIV-negative persons in a randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2015;61(4):572–80.CrossRefPubMedPubMedCentral Mulligan K, Glidden DV, Anderson PL, et al. Effects of emtricitabine/tenofovir on bone mineral density in HIV-negative persons in a randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2015;61(4):572–80.CrossRefPubMedPubMedCentral
46.
Zurück zum Zitat Kasonde M, Niska RW, Rose C, et al. Bone mineral density changes among HIV-uninfected young adults in a randomised trial of pre-exposure prophylaxis with tenofovir-emtricitabine or placebo in Botswana. PLoS ONE. 2014;9(3):1–9.CrossRef Kasonde M, Niska RW, Rose C, et al. Bone mineral density changes among HIV-uninfected young adults in a randomised trial of pre-exposure prophylaxis with tenofovir-emtricitabine or placebo in Botswana. PLoS ONE. 2014;9(3):1–9.CrossRef
47.
48.
Zurück zum Zitat Liu AY, Vittinghoff E, Sellmeyer DE, et al. Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco. PLoS ONE. 2011;6(8):e23688.CrossRefPubMedPubMedCentral Liu AY, Vittinghoff E, Sellmeyer DE, et al. Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco. PLoS ONE. 2011;6(8):e23688.CrossRefPubMedPubMedCentral
49.
Zurück zum Zitat Grant R, Mulligan, K., McMahan V, et al. Recovery of bone mineral density after stopping oral HIV preexposure prophylaxis. Conference on retroviruses and opportunistic infections [abstract 48LB]. Boston, Massachusetts: 2016;22–25 February. Grant R, Mulligan, K., McMahan V, et al. Recovery of bone mineral density after stopping oral HIV preexposure prophylaxis. Conference on retroviruses and opportunistic infections [abstract 48LB]. Boston, Massachusetts: 2016;22–25 February.
50.
Zurück zum Zitat Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomized, double-blind, phase 3, non-inferiority trials. Lancet. 2015;385(9987):2606–16.CrossRefPubMed Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomized, double-blind, phase 3, non-inferiority trials. Lancet. 2015;385(9987):2606–16.CrossRefPubMed
51.
Zurück zum Zitat Garrett KL, Cottrell ML, Prince HM, et al. Concentrations of TFV and TFVdp in female mucosal tissues after a single dose of TAF. Conference on retroviruses and opportunistic infections [abstract 102LB]. Boston, Massachusetts: 2016; 22–25 February. Garrett KL, Cottrell ML, Prince HM, et al. Concentrations of TFV and TFVdp in female mucosal tissues after a single dose of TAF. Conference on retroviruses and opportunistic infections [abstract 102LB]. Boston, Massachusetts: 2016; 22–25 February.
52.
Zurück zum Zitat Spinner CD, Boesecke C, Zink A, et al. HIV pre-exposure prophylaxis (PrEP): a review of current knowledge of oral systemic HIV PrEP in humans. Infection. 2016;44(2):151–8.CrossRefPubMed Spinner CD, Boesecke C, Zink A, et al. HIV pre-exposure prophylaxis (PrEP): a review of current knowledge of oral systemic HIV PrEP in humans. Infection. 2016;44(2):151–8.CrossRefPubMed
53.
Zurück zum Zitat Marcus JL, Glidden DV, Mayer KH, et al. No evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis. PLoS ONE. 2013;8(12):e81997.CrossRefPubMedPubMedCentral Marcus JL, Glidden DV, Mayer KH, et al. No evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis. PLoS ONE. 2013;8(12):e81997.CrossRefPubMedPubMedCentral
54.
Zurück zum Zitat Liu AY, Cohen SE, Vittinghoff E, et al. Preexposure prophylaxis for HIV infection integrated with municipal- and community-based sexual health services. JAMA Intern Med. 2016;176(1):75–84.CrossRefPubMedPubMedCentral Liu AY, Cohen SE, Vittinghoff E, et al. Preexposure prophylaxis for HIV infection integrated with municipal- and community-based sexual health services. JAMA Intern Med. 2016;176(1):75–84.CrossRefPubMedPubMedCentral
55.
Zurück zum Zitat Golub SA, Pena S, Boonrai K, Douglas N, Hunt M, Radix A. STI data from community-based PrEP implementation suggest changes to CDC guidelines. Conference on retroviruses and opportunistic infections [abstract 869]. Boston, Massachusetts: 2016; 22–25 February. Golub SA, Pena S, Boonrai K, Douglas N, Hunt M, Radix A. STI data from community-based PrEP implementation suggest changes to CDC guidelines. Conference on retroviruses and opportunistic infections [abstract 869]. Boston, Massachusetts: 2016; 22–25 February.
56.
Zurück zum Zitat Flash C, Landovitz R, Giler RM, et al. Two years of Truvada for pre-exposure prophylaxis utilization in the U.S. J Int AIDS Soc. 2014;17(4 Suppl 3):19730. Flash C, Landovitz R, Giler RM, et al. Two years of Truvada for pre-exposure prophylaxis utilization in the U.S. J Int AIDS Soc. 2014;17(4 Suppl 3):19730.
57.
Zurück zum Zitat Delaney KP, Sanchez T, Bowles K, Oraka E, DiNenno E, Sullivan P. Awareness and use of PrEP appear to be increasing among internet samples of US MSM. Conference on retroviruses and opportunistic infections [abstract 889]. Boston, Massachusetts: 2016; 22–25 February. Delaney KP, Sanchez T, Bowles K, Oraka E, DiNenno E, Sullivan P. Awareness and use of PrEP appear to be increasing among internet samples of US MSM. Conference on retroviruses and opportunistic infections [abstract 889]. Boston, Massachusetts: 2016; 22–25 February.
58.
Zurück zum Zitat Mayer K, Krakower D, Levine K, et al. Significant increases in HIV pre-exposure prophylaxis (PrEP) uptake in Boston, a Boston Community Health Center in 2014: who are the recent users? In: 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Vancouver; 2015. Mayer K, Krakower D, Levine K, et al. Significant increases in HIV pre-exposure prophylaxis (PrEP) uptake in Boston, a Boston Community Health Center in 2014: who are the recent users? In: 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Vancouver; 2015.
59.
Zurück zum Zitat Smith DK, Van Handel M, Wolitski RJ, et al. Vital signs: estimated percentages and numbers of adults with indications for preexposure prophylaxis to prevent HIV acquisition – United States, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(46):1291–5.CrossRefPubMed Smith DK, Van Handel M, Wolitski RJ, et al. Vital signs: estimated percentages and numbers of adults with indications for preexposure prophylaxis to prevent HIV acquisition – United States, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(46):1291–5.CrossRefPubMed
61.
Zurück zum Zitat Blumenthal J, Jain S, Krakower D, et al. Knowledge is power! Increased provider knowledge scores regarding pre-exposure prophylaxis (PrEP) are associated with higher rates of PrEP prescription and future intent to prescribe PrEP. AIDS Behav. 2015;19(5):802–10.CrossRefPubMedPubMedCentral Blumenthal J, Jain S, Krakower D, et al. Knowledge is power! Increased provider knowledge scores regarding pre-exposure prophylaxis (PrEP) are associated with higher rates of PrEP prescription and future intent to prescribe PrEP. AIDS Behav. 2015;19(5):802–10.CrossRefPubMedPubMedCentral
62.
Zurück zum Zitat Mimiaga MJ, White JM, Krakower DS, Biello KB, Mayer KH. Suboptimal awareness and comprehension of published preexposure prophylaxis efficacy results among physicians in Massachusetts. AIDS Care. 2014;26(6):684–93.CrossRefPubMed Mimiaga MJ, White JM, Krakower DS, Biello KB, Mayer KH. Suboptimal awareness and comprehension of published preexposure prophylaxis efficacy results among physicians in Massachusetts. AIDS Care. 2014;26(6):684–93.CrossRefPubMed
63.
Zurück zum Zitat Edelstein ZR, Salcuni PM, Restar A, et al. Early adopters and incident PrEP prescribing in a detailing campaign, 2014–2015. Conference on retroviruses and opportunistic infections [abstract 892]. Boston, Massachusetts: 2016; 22–25 February. Edelstein ZR, Salcuni PM, Restar A, et al. Early adopters and incident PrEP prescribing in a detailing campaign, 2014–2015. Conference on retroviruses and opportunistic infections [abstract 892]. Boston, Massachusetts: 2016; 22–25 February.
64.
Zurück zum Zitat Mayer K, Safren S, Haberer J, et al. Project PrEPare: high levels of medication adherence with continued condomless sex in U.S. men who have sex with men in an oral PrEP adherence trial. HIV Research for Prevention [abstract OA07.06 LB]. Cape Town, South Africa: 2014; 28–31 October. Mayer K, Safren S, Haberer J, et al. Project PrEPare: high levels of medication adherence with continued condomless sex in U.S. men who have sex with men in an oral PrEP adherence trial. HIV Research for Prevention [abstract OA07.06 LB]. Cape Town, South Africa: 2014; 28–31 October.
65.
Zurück zum Zitat Sherman MD, Kauth MR, Shipherd JC, Street RL Jr. Communication between VA providers and sexual and gender minority veterans: a pilot study. Psychol Serv. 2014;11(2):235–42.CrossRefPubMed Sherman MD, Kauth MR, Shipherd JC, Street RL Jr. Communication between VA providers and sexual and gender minority veterans: a pilot study. Psychol Serv. 2014;11(2):235–42.CrossRefPubMed
66.
Zurück zum Zitat Patel R, Chan P, Nunn A, et al. Missed opportunities to prescribe PrEP by primary care physicians in Saint Louis. Conference on retroviruses and opportunistic infections [abstract 891]. Boston, Massachusetts: 2016; 22–25 February. Patel R, Chan P, Nunn A, et al. Missed opportunities to prescribe PrEP by primary care physicians in Saint Louis. Conference on retroviruses and opportunistic infections [abstract 891]. Boston, Massachusetts: 2016; 22–25 February.
67.
Zurück zum Zitat Lanier Y, Castellanos T, Barrow RY, Jordan WC, Caine V, Sutton MY. Brief sexual histories and routine HIV/STD testing by medical providers. AIDS Patient Care STDs. 2014;28(3):113–20.CrossRefPubMedPubMedCentral Lanier Y, Castellanos T, Barrow RY, Jordan WC, Caine V, Sutton MY. Brief sexual histories and routine HIV/STD testing by medical providers. AIDS Patient Care STDs. 2014;28(3):113–20.CrossRefPubMedPubMedCentral
68.
Zurück zum Zitat Smith DK, Pals SL, Herbst JH, Shinde S, Carey JW. Development of a clinical screening index predictive of incident HIV infection among men who have sex with men in the United States. J Acquir Immune Defic Syndr. 2012;60(4):421–7.CrossRefPubMed Smith DK, Pals SL, Herbst JH, Shinde S, Carey JW. Development of a clinical screening index predictive of incident HIV infection among men who have sex with men in the United States. J Acquir Immune Defic Syndr. 2012;60(4):421–7.CrossRefPubMed
69.
Zurück zum Zitat Mayer KH, Krakower DS. Editorial commentary: scaling up antiretroviral preexposure prophylaxis: moving from trials to implementation. Clin Infect Dis. 2015;61(10):1598–600.CrossRefPubMedPubMedCentral Mayer KH, Krakower DS. Editorial commentary: scaling up antiretroviral preexposure prophylaxis: moving from trials to implementation. Clin Infect Dis. 2015;61(10):1598–600.CrossRefPubMedPubMedCentral
72.
Zurück zum Zitat Marcus JL, Volk JE, Pinder J, et al. Successful implementation of HIV preexposure prophylaxis: lessons learned from three clinical settings. Curr HIV/AIDS Rep. 2016;13(2):116–24.CrossRefPubMed Marcus JL, Volk JE, Pinder J, et al. Successful implementation of HIV preexposure prophylaxis: lessons learned from three clinical settings. Curr HIV/AIDS Rep. 2016;13(2):116–24.CrossRefPubMed
73.
Zurück zum Zitat Sikkema KJ, Watt MH, Drabkin AS, Meade CS, Hansen NB, Pence BW. Mental health treatment to reduce HIV transmission risk behavior: a positive prevention model. AIDS Behav. 2010;14(2):252–62.CrossRefPubMedPubMedCentral Sikkema KJ, Watt MH, Drabkin AS, Meade CS, Hansen NB, Pence BW. Mental health treatment to reduce HIV transmission risk behavior: a positive prevention model. AIDS Behav. 2010;14(2):252–62.CrossRefPubMedPubMedCentral
74.
Zurück zum Zitat Safren SA, Reisner SL, Herrick A, Mimiaga MJ, Stall R. Mental health and HIV risk in men who have sex with men. J Acquir Immune Defic Syndr. 2010;55(Suppl 2):S74–7.CrossRefPubMedPubMedCentral Safren SA, Reisner SL, Herrick A, Mimiaga MJ, Stall R. Mental health and HIV risk in men who have sex with men. J Acquir Immune Defic Syndr. 2010;55(Suppl 2):S74–7.CrossRefPubMedPubMedCentral
75.
Zurück zum Zitat Koblin BA, Husnik MJ, Colfax G, et al. Risk factors for HIV infection among men who have sex with men. AIDS. 2006;20(5):731–9.CrossRefPubMed Koblin BA, Husnik MJ, Colfax G, et al. Risk factors for HIV infection among men who have sex with men. AIDS. 2006;20(5):731–9.CrossRefPubMed
76.
Zurück zum Zitat Hirshfield S, Remien RH, Humberstone M, Walavalkar I, Chiasson MA. Substance use and high-risk sex among men who have sex with men: a national online study in the USA. AIDS Care. 2004;16(8):1036–47.CrossRefPubMed Hirshfield S, Remien RH, Humberstone M, Walavalkar I, Chiasson MA. Substance use and high-risk sex among men who have sex with men: a national online study in the USA. AIDS Care. 2004;16(8):1036–47.CrossRefPubMed
77.
Zurück zum Zitat Stall R, Paul J, Greenwood G, et al. Alcohol use, drug use and alcohol-related problems among men who have sex with men: the Urban Men’s Health Study. Addiction. 2001;96(11):1589–601.CrossRefPubMed Stall R, Paul J, Greenwood G, et al. Alcohol use, drug use and alcohol-related problems among men who have sex with men: the Urban Men’s Health Study. Addiction. 2001;96(11):1589–601.CrossRefPubMed
78.
Zurück zum Zitat Parker R, Aggleton P. HIV and AIDS-related stigma and discrimination: a conceptual framework and implications for action. Soc Sci Med. 2003;57(1):13–24.CrossRefPubMed Parker R, Aggleton P. HIV and AIDS-related stigma and discrimination: a conceptual framework and implications for action. Soc Sci Med. 2003;57(1):13–24.CrossRefPubMed
79.
Zurück zum Zitat Preston DB, D’Augelli AR, Kassab CD, Starks MT. The relationship of stigma to the sexual risk behavior of rural men who have sex with men. AIDS Educ Prev. 2007;19(3):218–30.CrossRefPubMed Preston DB, D’Augelli AR, Kassab CD, Starks MT. The relationship of stigma to the sexual risk behavior of rural men who have sex with men. AIDS Educ Prev. 2007;19(3):218–30.CrossRefPubMed
Metadaten
Titel
Pre-Exposure Prophylaxis: A Narrative Review of Provider Behavior and Interventions to Increase PrEP Implementation in Primary Care
verfasst von
Andrew Silapaswan, BS
Douglas Krakower, MD
Kenneth H. Mayer, MD
Publikationsdatum
19.10.2016
Verlag
Springer US
Erschienen in
Journal of General Internal Medicine / Ausgabe 2/2017
Print ISSN: 0884-8734
Elektronische ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-016-3899-4

Weitere Artikel der Ausgabe 2/2017

Journal of General Internal Medicine 2/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.